			DINITE IS CO						
		TRANSMITTAL LETTER TO THE UNITED STATES	ATTORNEY'S DOCKET NUMBER 245578						
		DESIGNATED/ELECTED OFFICE (DO/EO/US)	CLIENT REF. NO. 201422						
	•	CONCERNING A SUBMISSION UNDER 35 U.S.C. 371	U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/560,183						
		TIONAL APPLICATION NO. INTERNATIONAL FILING DATE	INTERNATIONAL APPLICATION NO.						
		P2004/008471   10 June 2004 (10.06.2004)	10 June 2003 (10.06.2003)						
	ME	THOD OF ADJUDICATING ON ACUTE AORTIC DISSECTION ANI	D REAGENT FOR ADJUDICATION						
		HAZUI et al.							
Apr	Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
1.		This is a FIRST submission of items concerning a filing under 35 USC 371 and	d 37 CFR 1.491.						
2.	$\boxtimes$	This is a SECOND or SUBSEQUENT submission of items concerning a filing	under 35 USC 371 and 37 CFR 1.491.						
3.		This is an express request to begin national examination procedures (35 USC	371(f)).						
4.		The US has been elected (PCT Article 31).							
5.		A copy of the International Application as filed (35 USC 371(c)(2))  a.  is attached hereto (required only if not communicated by the International Bureau.  b.  is not required, as the application was filed in the United States Received.	·						
6.		☐ An English language translation of the International Application as filed (35 USC 371(c)(2)).  a. ☐ is attached hereto.  b. ☐ has previously been submitted under 35 U.S.C. 154(d)(4).							
7.	Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3))  a.  are attached hereto (required only if not communicated by the International Bureau).  b.  have been communicated by the International Bureau.  c.  have not been made; however, the time limit for making such amendments has NOT expired.  d.  have not been made and will not be made.								
8.		An English language translation of the amendments to the claims under PCT	Article 19 (35 USC 371(c)(3)).						
9.		An oath or declaration of the inventor(s) (35 USC 371(c)(4)).							
10.		An English language translation of the annexes to the International Preliminar (35 USC 371(c)(5)).	y Examination Report under PCT Article 36						
11.	Nuc a. b.	Cleotide and/or Amino Acid Sequence Submission  Computer Readable Form (CRF)  Specification Sequence Listing on:  CD-ROM or CD-R (2 copies); or  Paper Copy  Statement verifying identity of above copies							
	Items 12 to 20 below concern other document(s) or information included:  12. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.								
'².		Form PTO-1449							
12		Copies of References (except for U.S. patents and applications)	YED 2.20 and 2.24 is included						
	$\exists$	An assignment for recording. A separate cover sheet in compliance with 37 C A FIRST preliminary amendment.	FR 3.26 and 3.31 is included.						
15.		A SECOND or SUBSEQUENT preliminary amendment.							
16. 17.		A substitute specification. A change of power of attorney and/or address letter.							
18.	_	Application Data Sheet Under 37 CFR 1.76							
	$\boxtimes$	Return Receipt Postcard							

SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

10/500 100								REF. NO. 1422	
The following fees are submitted:  CALCULATIONS PTO USE ONLY									
21. Basic national fee									
22. Examination Fee									
If international prelimin		ort prepare	ed by USPTO and	all claims	satisfy		<u>_</u>		
provisions of PCT Artic					\$ 0		\$		
All other situations					\$200				
23. Search Fee									
USPTO was ISA					\$100		•		
Search report provided					\$400	İ	\$		
All other situations					\$500				
					, 22 AND 23 =		\$		
☐ Additional fee for s	specification and dra	wings filed	in paper over 100	0 sheets (	excluding				
sequence listing or cor						1	\$		
each additional 50 she	ets of paper or fracti	on thereof			*		•		
			of each additional 50	or fraction	1				
Total Sheets	Extra Sheets		(round up to a whole		RATE	1			
- 100 =	/ 50 =		(		x \$250		\$		
☐ Surcharge of \$130		ational fee	or oath or declara	tion later			<del></del>		
from the earliest claim	ed priority date (37 C	FR 1 492	h))	illon later	man 50 monus		\$		
CLAIMS	NUMBER FILI		NUMBER EXT	rp A	RATE	_	Ψ		
Total Claims	NOWBERFILE	- 20=	NUMBEREAL	IRA		<b> </b>	\$		
	<u>-</u>	- 3 =			x \$ 50	<del> </del>	\$		
Independent Claims	NIT OL AINE(O) (if				x \$200	<del> </del>			
MULTIPLE DEPENDE	:NI CLAIM(S) (If ap	piicabie)		21/2 2 11	+ \$360	<b></b>	\$		
					CULATIONS =	ļ	\$0.00		
Applicant claims si	mall entity status. Se	ee 37 CFR	1.27. Fees above	e are redu		<u> </u>	\$( )		
					SUBTOTAL=	<u> </u>	\$0.00		
☐ Processing fee of \$		nglish Tra	nslation later than	30 month	s from the				
earliest claimed priority	y date.					<u> </u>	\$		
					ATIONAL FEE=		\$0.00		
	he enclosed assignn						_		
accompanied by an ap	propriate cover shee	et (37 CFR	3.28, 3.31). \$40	per prope	erty.		\$		
			TO'	TAL FEE	S ENCLOSED=		\$0.00		
						Ar	nount to be:	\$	
							refunded	9	
						Α	mount to be	\$	
							charged:	9	
a. 🛛 No fee is beli	eved to be due.								
b. 🛛 Please charg	e Deposit Account N	o. 12-1216	S the total fee indic	cated abo	ve.				
	sioner is hereby auth					uired.	or credit anv	overpayment to	
Deposit Acco	unt No. 12-1216. A	duplicate of	copy of this sheet i	is enclose	ed.		,	, , , , , , , , , , , , , , , , , , , ,	
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.									
				n	1 11 1		1		
SEND ALL CORRESP	SEND ALL CORRESPONDENCE TO CUSTOMER NO. 23460:								
John Klyk, Jr., Registration Ng. 30,763									
23460 LEYDIG, VOIT & MAYER, LAD.									
Two Prudential Plaza, Suite 4900									
180 North Stetson Avenue									
Chicago, Illinois 60601-6780									
(312) 616-5600 (telephone)									
			(3.	12) 616-5	5700 (facsimile	)			
			Da	ate: Marc	ch 9, 2006				

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO. ATTORNEY DOCKET NO. CLIENT REF. NO. PCT/JP2004/008471 10/560,183 245578 201422 EV 708752963 US March 9, 2006 "Express Mail" Mailing Number Date of Deposit I hereby certify that this transmittal document with respect to the U.S. national phase of the above-referenced International Patent Application, including all of the items listed thereon as enclosures, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. John Kilyk, Jr. Typed or Printed Name of Person Making Deposit Signature of Person Making Deposit

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application No. 10/560,183

Applicant: Hazui et al.

Filed: December 9, 2005

TC/AU: Unassigned

Examiner: Unassigned

Docket No.: 245578 (Client Reference No. 201422)

Customer No.: 23460

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date

In re Appln. of Hazui et al. Application No. 10/560,183

		rst Office Action on the merits; or (d) before the mailing of a first Office Action ne filing of a request for continued examination under 37 CFR 1.114.
	37 CF	(a), (b), (c) or (d) above, but before the mailing date of a final action under R 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that vise closes prosecution in the application, and includes <i>one</i> of:
		the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
	$\bigcap$	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
	under and or 37 CF	the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance 37 CFR 1.311, or an action that otherwise closes prosecution in the application, a or before payment of the issue fee, and includes the Statement under R 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as th in 37 CFR 1.17(p) (see "Fees" below).
	payme contai 37 CF \$180 a NOTE: May 29	the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before ent of the issue fee, and within thirty days of receiving each item of information ned in the Information Disclosure Statement, and includes the Statement under R 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of as set forth in 37 CFR 1.17(p) (see "Fees" below).  This is for original applications except applications for a design patent, filed on or after 0, 2000, wherein a paper containing only an Information Disclosure Statement in compliance of CFR 1.97 and 1.98 is being filed.
Copie	s of the	References
	Copie herew	s of all of the references listed on the enclosed Form 1449 are enclosed ith.
	Form	s of U.S. patents and patent applications that are listed on the accompanying 1449 are not enclosed herewith. Copies of other references identified on the apanying Form 1449 are enclosed herewith.
	releva an Engaction degree	ned to each reference not in the English language is a concise explanation of the nce pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or glish-language abstract, or an English-language version of the search report or by a foreign patent office in a counterpart foreign application indicating the c of relevance found by the foreign office is being submitted in lieu of a concise nation of the relevance pursuant to 37 CFR 1.98(a)(3).
$\boxtimes$	A cop	y of the foreign search report is enclosed herewith.
	parent	eferences listed on the enclosed Form 1449 were previously identified in the application(s) of the present application, and copies of the references were hed at that time. Accordingly, additional copies of the references are not

In re Appln. of Hazui et al. Application No. 10/560,183

submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

U.S. APPLI	CATIONS	STATUS (check one)			
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED	
1.					
2.					
3.					

Stater	nent under 37 CFR 1.97(e)
	The <b>undersigned</b> hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
	The <b>undersigned</b> hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.
State	nent under 37 CFR 1.704(d)
	The <b>undersigned</b> hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
Fees	
	No fee is owed by the applicant(s). Charge Deposit Account No. 12-1216 in the amount of \$180.00 (37 CFR 1.17(p)). (A duplicate copy of this communication is enclosed for that purpose.)

In re Appln. of Hazui et al. Application No. 10/560,183

## **Authorization to Charge Additional Fees**

 $\boxtimes$ 

If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)

### Instructions as to Overpayment

Credit Account No. 12-1216.
Refund

John Kilyk, Jr., Reg. Vo. 30,763 LEYDIG, VOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900 180 North Stetson Avenue Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

Date: March 9, 2006

IDS (Revised 2005 08 01)

Please type a plus sign (+) inside this box —	干
---	---

Substitute for form 1449A/B/PTO

# **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	

Complete if Known					
Application Number	10/560,183				
Filing Date	December 9, 2005				
First Named Inventor	Hazui et al.				
Group Art Unit	Unassigned				
Examiner Name	Unassigned				
Attorney Docket Number	245578				
Client Reference No.	201422				

			U	S. PATENT DOCUMENTS		
		U.S. Patent Document				I .
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		<del></del>	+			
						<u> </u>
					<u> </u>	
		· · · · · · · · · · · · · · · · · · ·				

				FOREIGN	N PATENT DOCUMENTS			
		Fo	reign Patent Documer	nt			Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
								† ···-

Doc.	1 /hook magazing journal carial symposium estalag etc.) data maga/a) waliona i (-) [7]		slation
No.			No*+
AA	NAKAJIMA et al., J. Vascular Surgery, 26(4): 609-615 (Oct. 1997)		<u> </u>
ΑB	SHIMAMURA et al., J. Jpn. Assn. Thorac. Surg., 46: 616-621 (1998)	***	X <sup>+</sup>
AC	VAZIRI et al., Am. J. Med., 93: 651-657 (Dec. 1992)		
ΑD	WATANABE et al., Clinical Biochemistry, 34: 257-263 (2001)		
ΑE	WEBER et al., Chest, 123(5): 1375-1378 (May 2003)		
ΑF	YOSHIMURA et al., Kyobu Geka, 49(11): 943-946 (1996)		X <sup>+</sup>
			<del>  ^</del>
	AA AB AC AD AE	No. (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.  A A NAKAJIMA et al., <i>J. Vascular Surgery</i> , 26(4): 609-615 (Oct. 1997)  A B SHIMAMURA et al., <i>J. Jpn. Assn. Thorac. Surg.</i> , 46: 616-621 (1998)  A C VAZIRI et al., <i>Am. J. Med.</i> , 93: 651-657 (Dec. 1992)  A D WATANABE et al., <i>Clinical Biochemistry</i> , 34: 257-263 (2001)  A E WEBER et al., <i>Chest</i> , 123(5): 1375-1378 (May 2003)	No. (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.  A A NAKAJIMA et al., <i>J. Vascular Surgery</i> , 26(4): 609-615 (Oct. 1997)  A B SHIMAMURA et al., <i>J. Jpn. Assn. Thorac. Surg.</i> , 46: 616-621 (1998)  A C VAZIRI et al., <i>Am. J. Med.</i> , 93: 651-657 (Dec. 1992)  A D WATANABE et al., <i>Clinical Biochemistry</i> , 34: 257-263 (2001)  A E WEBER et al., <i>Chest</i> , 123(5): 1375-1378 (May 2003)

Examiner Signature	0-1-0-11
CABITITIES SIGNALUIE	Date Considered
_	

<sup>\*</sup> A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).